New Gene-Engineered immune cells offer hope for Hard-to-Treat leukemia
NCT ID NCT07361029
First seen Jan 28, 2026 · Last updated May 09, 2026 · Updated 15 times
Summary
This early-phase trial tests a new type of immunotherapy called CD19 CAR T cells in adults (ages 18-75) with acute lymphoblastic leukemia that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in the lab to target and kill cancer cells. The main goals are to find the safest dose and check for side effects, while also looking at how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
King Faisal Specialist Hospital and Research Center
RECRUITINGRiyadh, Riyadh Region, Saudi Arabia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.